Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
April 16 2024 - 8:00AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced that the
U.S. Patent and Trademark Office (USPTO) has issued U.S. patent
10,143,419 ('419 patent) entitled “Systems and Methods for Treating
Cancer and/or Augmenting Organ Function.”
The issued patent is directed to technology
including, but not limited to, systems, methods and devices for
interventionally treating cancerous tumors and cancer related pain.
The Company is initially advancing the development of its
technology to address pancreatic cancer-related pain.
Lori Bisson, Chief Executive Officer of
Autonomix, commented, “The issuance of this U.S. patent represents
a significant milestone for the Company and the ongoing development
of our potentially breakthrough technology. We place a high
priority on protection of our novel technology and have invested in
building a deep patent portfolio of 15 patent families with over
100 patents, issued and pending. We are committed to advancing the
development of our technology with the goal of bringing nerve
targeted therapy to patients and believe this patent further
validates the potential of our technology. In addition to our
initial focus on the successful completion of our first in man
study for pancreatic cancer pain, a multi-billion dollar market
opportunity, we are investigating additional uses for the
technology in other high-value indications with unmet needs.”
The Company’s catheter-based sensing technology
is being developed to do two things: sense neural signals
associated with pain or disease and precisely target those nerves
for treatment. Autonomix believes this technology is a better
alternative to the current approaches commonly used today, where
doctors either rely on systemic drugs like opioids that lose
effectiveness and have unwanted side effects or treat suspected
areas blindly in hopes of hitting the right nerves, an approach
that is often inaccurate and can miss the target and even cause
collateral damage to surrounding parts of the body.
The Company is initially developing its
technology to address pancreatic cancer-related pain. Current
approaches, primarily relying on opioids or invasive ethanol
injections, can provide only limited relief and may lead to risky
side effects. For more information about the Company’s technology,
please visit autonomix.com.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and needs an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward looking statements in this press release
include, without limitation, the potential of the technology to
treat hypertension and to complete its clinical study in pancreatic
cancer pain. Such forward-looking statements can be identified by
the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’
‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’
‘plans,’ and ‘proposes.’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering circular filed
with the U.S. Securities and Exchange Commission (“SEC”) on January
26, 2024. Forward-looking statements speak only as of the date of
the document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From Sep 2023 to Sep 2024